ClinicalTrials.gg
CompletedNCT00002000Updated Jun 24, 2005

A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients

An interventional study of Valacyclovir hydrochloride and Acyclovir in Herpes Simplex and HIV Infections, sponsored by Glaxo Wellcome. Completed at 22 sites in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing valacyclovir in Herpes Simplex — none open to participants now, none under way, none of them phase 3. Valacyclovir · Herpes Simplex.

No phase
5 of 24
none open now
Registered
1st of 24
by date
Lead sponsor
4 of 24
Glaxo Wellcome

Among the 24 studies testing valacyclovir in Herpes Simplex, this one is one of 5 with no phase, and was the 1st registered.

Herpes Simplex

166 studies on the registry are indexed under Herpes Simplex; 12 are open to participants now.

Browse Herpes Simplex studies →

Open to participants now

None of the 24 studies testing valacyclovir in Herpes Simplex is open now. The open studies under Herpes Simplex, anywhere →

About valacyclovir

Valacyclovir: first FDA approval 1995 (VALTREX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Herpes Simplex studies recruiting now, 4 (40%) set no upper age limit and 1 (10%) stops at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing valacyclovir in Herpes Simplex as a file.
02

Study summary

To evaluate the safety and efficacy of oral valacyclovir hydrochloride (256U87) vs. acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients (CD4 greater than or equal to 100).

Read the detailed description

Efficacy variables include the length of the episode, the time to lesion healing, the duration and severity of pain/discomfort, the duration of viral shedding, the proportion of patients with aborted episodes, the proportion of patients requiring extended therapy.

03

Conditions studied

  • Herpes Simplex
  • HIV Infections

Keywords

  • Acyclovir
  • Acquired Immunodeficiency Syndrome
  • AIDS-Related Complex
  • Antiviral Agents
  • Anus Diseases
  • Herpes Genitalis
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must have the following:

  • -infected individual ( = or > 100) with a history of recurrent anogenital herpes.
  • Signed the consent form or present a signed parental consent form if below 18 years.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Hepatic impairments as evidenced by a three-fold increase from the in alanine or . Impairment of renal function as evidenced by any elevation above the upper limit of normal for serum creatinine. History of to acyclovir. Malabsorption or vomiting that would, in the investigators opinion, potentially limit the retention and absorption of oral therapy.

Patients with the following are excluded:

  • Hepatic impairment as evidenced by a three-fold increase from the upper limit of normal in alanine or aspartate transaminase. Impairment of renal function as evidenced by any elevation above the upper limit of normal for serum creatinine.
  • History of hypersensitivity to acyclovir. Malabsorption or vomiting that would, in the investigator's opinion, potentially limit the retention and absorption of oral therapy.

Prior Medication:

Excluded:

  • Systemic antiherpes or immunomodulatory therapy within 30 days prior to entry.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
06

Study locations

22 sites
  • Univ of South Alabama
    Mobile, Alabama 36604, United States
  • ViRx Inc
    San Francisco, California 94103, United States
  • UCSF - San Francisco Gen Hosp
    San Francisco, California 94110, United States
  • Denver Public Health Dept / Disease Control Services
    Denver, Colorado 80204, United States
  • West Haven Veterans Administration Med Ctr
    West Haven, Connecticut 06516, United States
  • Univ of South Florida
    Tampa, Florida 33612, United States
  • Emory Univ School of Medicine
    Atlanta, Georgia 30303, United States
  • Northwestern Memorial Hosp
    Chicago, Illinois 60611, United States
  • Rush Presbyterian - Saint Luke's Med Ctr
    Chicago, Illinois 60612, United States
  • Infectious Diseases Research Clinic / Indiana Univ Hosp
    Indianapolis, Indiana 46202, United States
  • Louisiana State Univ Med School
    New Orleans, Louisiana 701122822, United States
  • Univ of Mississippi Med Ctr
    Jackson, Mississippi 39216, United States
  • Univ of New Mexico School of Medicine
    Albuquerque, New Mexico 87131, United States
  • Saint Vincent's Hosp and Med Ctr
    New York, New York 10011, United States
  • Univ of Cincinnati
    Cincinnati, Ohio 452670560, United States
  • Portland Veterans Adm Med Ctr / Rsch & Education Grp
    Portland, Oregon 97210, United States
  • Roger Williams Med Ctr
    Providence, Rhode Island 02908, United States
  • Vanderbilt School of Medicine
    Nashville, Tennessee 37232, United States
  • Univ TX Galveston Med Branch
    Galveston, Texas 77550, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Infectious Disease Physicians Inc
    Annandale, Virginia 22203, United States
  • Univ of Washington / Pacific Med Ctr
    Seattle, Washington 98144, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002000
Lead sponsor
Glaxo Wellcome
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 1996. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valacyclovir · Acyclovir

Start the discussion